416 related articles for article (PubMed ID: 32821164)
1. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
[TBL] [Abstract][Full Text] [Related]
4. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study.
Shen B; Jiang H; Wang L; Qian J; Shu Y; Chen P; Mao G; Liu B; Zhang X; Liu C; Wu J; Li X; Cai W; Shen W; Wang Q; He J; Hua D; Zhang Z; Zhang Y; Feng J
Onco Targets Ther; 2020; 13():4457-4464. PubMed ID: 32547076
[TBL] [Abstract][Full Text] [Related]
8. Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01).
Ma Y; Zhao W; Sun P; Deng W; Deng J; Zong H; Wang J; Guo Y; Liu H; Cang S; Shang K; Chen X; Wang J; He D; Wu G; Zhang Z; Zhang L; Xu F; Tian C; Qiao C; Chen G; Zhang G; Ma T; Gao L; Zhang G; Liu J; Eslick GD; Almhanna K; Lino-Silva LS; Aprile G; Li N; Luo S
Ann Transl Med; 2022 Dec; 10(24):1372. PubMed ID: 36660622
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer.
Li N; Bai C; Zhang R; Ma L; Ren X; Zhang J; Fu Z; Zhao L
Transl Oncol; 2021 Feb; 14(2):101004. PubMed ID: 33383486
[TBL] [Abstract][Full Text] [Related]
11. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer.
Cui Q; Mao Y; Wu D; Hu Y; Ma D; Zhang L; Liu H
Front Oncol; 2022; 12():952494. PubMed ID: 36387189
[TBL] [Abstract][Full Text] [Related]
12. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
14. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Xu J; Liu X; Yang S; Shi Y
Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
[TBL] [Abstract][Full Text] [Related]
15. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract][Full Text] [Related]
16. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
Zhao S; Fan N; Li H; Liu J; Huang F; Chen Y; Zhou M; Yu J; Lin R
Ann Transl Med; 2020 Oct; 8(19):1233. PubMed ID: 33178765
[TBL] [Abstract][Full Text] [Related]
17. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
18. An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202).
Wang X; Zhang R; Du N; Yang M; Zang A; Liu L; Yu J; Gao J; Zhang J; Fu Z; Ren Y; Ma L; Guo J; Li Q; Li X; Fan Z; Song X; Liu Z; Zhang Y; Li G; Yu Z; Diao J; Jia J; Liang F; Wang H; Sun J; Gao Y; Yang P; Bai C; Ren X; Zhong D
Ther Adv Med Oncol; 2020; 12():1758835920905424. PubMed ID: 32218807
[TBL] [Abstract][Full Text] [Related]
19. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
20. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
